Cannabis News

Proprietary spray delivers micro doses of psilocybin or N-acetylcysteine for treatment of PTSD and traumatic brain injury

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") announced today the completion and testing of the proof-of-concept prototype of its proprietary nasal mist device. As announced on December 3, 2020, the Company engaged VisionWorks Engineering of San Diego, CA to complete this first phase of development. Lobe's nasal mist device delivers "micro doses" of pharmaceutical agents such as a psilocybin and N-acetylcysteine ("NAC") at preselected dosages.

Philip Young, CEO of Lobe states "Advancing through the initial development and testing of our innovative nasal mist device will position Lobe as the leader in the delivery of effective therapeutics to treat patients suffering from mild traumatic brain injury, post-traumatic stress disorder, and other mental health conditions. We intend to further the development of this device leading to commercialization. Completing the development of this device will enable the patients to easily treat themselves where they live and work."

During the first phase of development of the device, a test platform was built. The platform was then used to quantify key characteristics of the actuator, atomizer, and control system. The testbed was also used to refine the mist volume, quality, and spray pattern. The results reflect a clear path for delivering precise doses of drugs to the upper region of the nasal cavity. The completion of the prototype phase is an important milestone towards the ultimate goal of developing effective delivery methods for commercialization.

Lobe holds several provisional patent applications, including the nasal mist device entitled "Device and Method for the Treatment of Traumatic Brain Injuries and Post-Traumatic Stress Disorder". Once completed, the device design will allow for the precise control and delivery of medicines through the nasal cavity directly to the olfactory bulb for faster and more efficient uptake of psilocybin and other medicines that target the brain.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, progression with nasal mist device engineering and commercialization, benefits of the nasal mist device for delivery of medicines, the pursuit of M&A initiatives, development of effective delivery methods and commercialization potential of the nasal mist device, research and development using NAC and psilocybin and growth of the business, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company's corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74818

News Provided by Newsfile via QuoteMedia

Lobe Sciences

Lobe Sciences


Keep reading...Show less
close-up of a gavel

Cannabis Weekly Round-Up: Court Case Begins for CannTrust Execs

The misdeeds of three former CannTrust executives severely impacted investors, a lawyer said in court this past week.

Elsewhere in Canada, a cannabis producer showed market watchers encouraging signs as part of its latest financial report.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less

TerrAscend and Cookies Celebrate the Grand Opening of Cookies Jackson

TerrAscend's Gage Cannabis Opens Fourth Cookies Dispensary in Michigan

TerrAscend Corp. ("TerrAscend" or the "Company") (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that its subsidiary, Gage Cannabis Co. ("Gage"), opened a new flagship cannabis provisioning center in Jackson, Michigan . Located at 118 N Columbus Street, the dispensary will be operated by Gage through a partnership with Cookies, the leading lifestyle and cannabis brand in North America .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Opening Medical Marijuana Dispensary in Hobe Sound, Florida

New dispensary expands patient access to medical cannabis; grand opening specials available

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of a new medical dispensary in Hobe Sound, Florida . Located at 10835 SE Federal Hwy., the doors will open at 9 a.m. on December 2 with ongoing regular hours of 9 a.m. to 9 p.m. from Monday through Saturday and 10 a.m. to 8 p.m. on Sunday .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

TerrAscend Appoints Seasoned Finance Professional, Ira Duarte, to Board of Directors

TerrAscend Corp. ("TerrAscend'' or the "Company") (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced the appointment of Ira Duarte to its Board of Directors, effective immediately. In addition, Ms. Duarte will serve as the Chair of the Audit Committee of the Board of Directors.

Ms. Duarte is an accomplished senior finance professional with more than 25 years of experience in a variety of finance, accounting and auditing leadership roles. She currently serves as Chief Financial Officer of Veloxis Pharmaceuticals, Inc. ("Veloxis"), a fully integrated specialty pharmaceutical company focused on the global development and commercialization of medications utilized by organ transplant patients. Prior to joining Veloxis, Ms. Duarte served as Senior Director of Corporate Finance for Chiesi USA , Inc. and Director of Accounting and Financial Planning for Cornerstone Therapeutics, Inc., where she was a core member of the team that guided the sale of Cornerstone Therapeutics, Inc. to Chiesi Farmaceutici S.p.A. Ms. Duarte previously held various roles from Staff to Senior Manager at Ernst & Young Global Limited, where she was responsible for managing audits, Securities Exchange Commission filings, and initial public offerings services for clients. A Certified Public Accountant, Ms. Duarte holds a BS in Accounting from Florida Atlantic University .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Curaleaf Announces December Investor Community Conference and Event Participation

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced that members of Curaleaf's executive management team will be participating in the following investor community conferences and events during December 2022 .

  • Cowen's 5 th Annual Cannabis Conference
    December 6, 2022
    Matt Darin , Chief Executive Officer of Curaleaf, will be participating in a fireside chat with Vivien Azer , Managing Director at Cowen, on December 6 at 1:20 – 1:50 p.m. ET .
    Curaleaf management will also be hosting investor meetings.

  • Stifel Canada's 3 rd Annual Future of Healthcare Conference
    December 7, 2022
    Matt Darin , Chief Executive Officer of Curaleaf, will be participating in a lunch panel with Andrew Partheniou , Vice President at Stifel, on December 7 at 12 – 12:55 p.m. ET .

For more information regarding upcoming Curaleaf financial community conference and event participation as well as details to access the webcasts please visit Curaleaf's IR website at https://ir.curaleaf.com/events .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Announces December 2022 Event Participation

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned participation in upcoming conferences and events in December.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

  • Cowen 5 th Annual Cannabis Conference, December 6, 2022 : Founder and CEO Kim Rivers will participate in a panel discussion and investor meetings.
  • Stifel 3 rd Annual Future of Healthcare Conference, December 7, 2022 : President Steve White will participate in a panel discussion.
  • Arcview Access Cannabis Investment Summit, December 8, 2022 : Founder and CEO Kim Rivers will participate in a panel discussion.

Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events-presentations

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
Twitter: @Trulieve

Investor Contact
Christine Hersey , Executive Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Rob Kremer , Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-december-2022-event-participation-301690946.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2022/01/c9826.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×